In colon cancer, a new murine monoclonal anti-TNFR2 antibody (TY101) therapy combined with R848 (a synthetic TLR7/8 agonist) and HMGN1 (N1, a dendritic cell-activating TLR4 agonist) synergistically inhibits murine colon cancer and is more effective when compared with the single treatment with any of the above-mentioned drugs (115). Here, HMGN1 is linked to malignant colon neoplasm.